New research emerging from the University of California, Davis, challenges the emerging narrative that psychedelic compounds like psilocybin, commonly known as magic mushrooms, may offer universal relief for mental health disorders, especially postpartum depression. This groundbreaking study, published in the prestigious journal Nature Communications, presents a meticulously conducted experimental investigation revealing that psilocybin, when administered during the postpartum period, may exacerbate rather than alleviate symptoms associated with maternal mood disorders.
The interdisciplinary team coordinated by UC Davis’s Institute for Psychedelics and Neurotherapeutics (IPN) undertook a novel approach by employing a uniquely designed mouse model to simulate postpartum depression. Their innovative model subjected mouse mothers to social stressors that mimic environmental challenges known to contribute to maternal depression, thereby creating a powerful analog for studying the neurobehavioral consequences of psychedelic drug administration in the context of the postpartum period. This approach allowed for a nuanced exploration into how psilocybin interacts with the distinct neurochemical milieu characteristic of the postpartum female brain.
Contrary to prevailing assumptions, psilocybin administration produced a pronounced amplification of anxiety and depressive-like behaviors in mother mice. These behavioral alterations were not fleeting but persisted robustly for two weeks following a single dose, signaling potentially long-lasting neuropsychological consequences. Particularly striking was the observation that these effects extended beyond the treated mothers, with offspring displaying measurable anxiety and depression-like symptoms well into adulthood, implicating intergenerational transmission of adverse outcomes potentially mediated through lactation.
This phenomenon underscores the complexity of psilocybin’s pharmacodynamics, especially given its known capacity to promote neuronal plasticity and have beneficial effects in other mental health contexts such as treatment-resistant depression and PTSD. The study draws attention to the critical role that ovarian hormones may play in modifying serotonergic pathways — the main pharmacological target of psychedelics — which in turn may drastically alter drug responses in postpartum individuals. These neuroendocrine interactions have been markedly underexplored prior to this research.
Olson, one of the study’s senior authors and the director of IPN, emphasized the nuanced implications of these findings, noting that while psychedelics hold immense promise, their efficacy and risk profile are likely not universal. “There are different patient populations,” he remarked, highlighting the danger of oversimplifying the therapeutic potential of compounds like psilocybin without sufficient consideration for physiological context, such as hormonal status during the postpartum period.
Heralding the importance of mechanistic rigor, co-author Danielle Stolzenberg elaborated on the novel postpartum depression mouse model utilized. This model psychologically stresses mothers by introducing a social threat—an intruder male mouse—thereby destabilizing maternal behaviors. Stressed mouse mothers avoided interaction with their pups, a parallel to the bonding difficulties reported in human postpartum depression. The model’s translational relevance strengthens the study’s conclusions about psilocybin’s adverse impact under conditions that closely approximate human maternal mood dysregulation.
The persistent behavioral impairments seen in psilocybin-treated mothers include increased avoidance of offspring and heightened anxiety measures, which worryingly persisted even after physical separation from the pups. The robustness and longevity of these symptoms raise critical questions about the appropriateness of psychedelic use in postpartum individuals, a demographic whose neurochemical and hormonal landscape diverges markedly from other groups.
Another dimension of the study that garnered significant attention was the transmission of drug effects to the next generation. Offspring born to psilocybin-exposed mothers exhibited significantly elevated anxiety and depressive metrics weeks after weaning, and biochemical analyses detected psilocin—psilocybin’s active metabolite—within their brains. This suggests lactational transfer as a vector for developmental neurotoxicity, thereby implicating maternal drug exposure as a potential risk factor for enduring neurodevelopmental disorders in progeny.
Statistically, the study’s findings were dichotomous when comparing postpartum mothers to virgin females: only the mothers exhibited the adverse response. This sharp distinction implicates ovarian hormone-dependent modulation of serotonergic signaling as a pivot point influencing the psychedelic’s neuropsychological outcomes. It prods the scientific community to recognize and further interrogate the intricate biochemical landscape underpinning sex- and state-specific drug efficacy and safety.
This revelation has significant implications for clinical translation. The potential therapeutic utility of psilocybin for mood disorders must be carefully contextualized to avoid inadvertent harm, particularly in vulnerable populations such as postpartum women. Scrutiny of the hormonal milieu alongside serotonergic dynamics should become central to developing precision medicine frameworks for psychedelic-assisted therapies.
The broader context of this research positions the UC Davis IPN as a leading force in advancing the frontier of psychedelic science. Their commitment to exploring both the promising and precarious facets of psychedelic compounds ensures a balanced, scientifically rigorous dialogue. Moreover, the interdisciplinary nature of the IPN consortium—encompassing fields such as anthropology, genomics, chemistry, and neuropharmacology—enables comprehensive investigation into multifaceted aspects of these drugs.
Finally, this research serves as a cautionary tale about the complexity of brain chemistry in postpartum mental health and challenges facile assumptions about the universal applicability of psychedelics. It highlights the necessity for targeted, population-specific therapeutic strategies that respect the nuanced interplay of hormonal, neurological, and developmental factors—a crucial stride toward safer psychedelic medicine.
Subject of Research: Animals
Article Title: Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring
News Publication Date: 30-Sep-2025
Web References: https://www.nature.com/articles/s41467-025-64371-5
References: Olson, D. E., Stolzenberg, D., Hatzipantelis, C., et al. (2025). Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring. Nature Communications. DOI: 10.1038/s41467-025-64371-5
Keywords: Depression, Psychopharmacology, Pharmaceuticals, Psychological science
